Scientific Symposium: Evotec’s Cutting-Edge Proteomics in Protein Degradation and Biologics

Biography

Carleen Kluger, Group Leader of Clinical Proteomics at Evotec, has built a remarkable career at the intersection of (bio)physics and biology. Throughout her academic journey, she delved into complex biological processes, leveraging cutting-edge technologies such as molecular tension sensors and high-resolution imaging-based methods. Evolving from a bioinformatician to a leader in clinical proteomics, Carleen spearheaded the implementation of novel mass spectrometry-based approaches for biofluids and tissues from humans and animals.

In her role, Carleen collaborates closely with clients to develop innovative protein biomarkers that enhance the success of pre-clinical and clinical studies across diverse therapeutic areas, from neurodegeneration to oncology and rare diseases. Embracing a curiosity for exploring new frontiers, her team pioneers’ technologies like extracellular vesicle enrichment, nanoparticle-based proteomics, and multi-omics data integration.

Biography

Dr. Christoph Schaab joined Kinaxo Biotechnolgies, which now is part of the Evotec, in 2008. He started as Head of Bioinformatics and supervised projects in the area of proteomics, biomarker discovery, and data management. Since 2018, he has been heading the proteomics & metabolomics unit globally and operations at the Munich site. Christoph has many years of experience in proteomics, bioinformatics, machine learning, and software and database development.

From 2008 to 2017, he was affiliated with the group of Prof. Matthias Mann at the Max Planck Institute of Biochemistry. Before joining Kinaxo and Evotec, he worked as group leader at GPC Biotech, where he was responsible for statistical analysis of gene expression and screening data as well as software and database development. Christoph studied physics at the Ludwig-Maximilians University in Munich, where he received a doctoral degree in theoretical physics.

Biography 

Since 2020 Markus Dangl serves as Executive Vice President at Evotec, leading the internal Oncology and I&I RnD organization and portfolio. He joined Evotec from Achilles Therapeutics, where he was as CSO responsible for the development and clinical translation of TIL-based cancer therapies. Prior to that, he held the position as as Senior Vice President for Research and Development at Medigene AG, working on autologous T cell product candidates.

Markus spent 15 years at Roche in Germany, Singapore and the US, holding various managerial positions and was involved in the design, execution and clinical transition of multiple oncology projects. He holds a PhD in Biochemistry from the University of Innsbruck in Austria.

Biography

Dr. Andreas Tebbe joined Kinaxo Biotechnolgies, which now is part of Evotec, in 2007, as Director Mass Spectrometry, setting up a high-end mass spectrometry platform for quantitative proteomics applications. Since 2020, he has been heading the proteomics & metabolomics Mass Spectrometry unit globally across both proteomics & metabolomics sites Munich and Toulouse. Andreas has many years of experience in mass spectrometry-based proteomics. He was decisively involved in transforming Evotec’s mass spectrometry unit into a world leading industrial scale MS facility delivering unparalleled performance.

Before joining Kinaxo and Evotec, he worked as a post doc at the Roche Centre for medical genomics establishing quantitative proteomics approaches to study drug-target interactions. Andreas studied Biochemistry at the Ruhr University in Bochum and performed his doctoral degree at the Max-Planck-Institute of Biochemistry in Martinsried.

Biography

Dr. Andreas Weiss is currently the Senior Vice President for Protein Homeostasis at Evotec where he pioneered the development of novel degraders hijacking disease relevant unique E3 ligases as well as developing bifunctional small molecule engagers of the autophagy pathway and the nuclear shuttling machinery. He also held the strategic and scientific leadership role in a significantly sized collaboration emphasizing the development of molecular glues with BMS.

Before Evotec, Dr. Weiss co-founded Promidis, where he was the Scientific Director for Drug Discovery and Technology overseeing the development of translational assays for curing neurodegenerative proteinopathies. Previously, during his time with Novartis Pharma, Dr. Weiss focused on the development of detection methods and therapeutics for misfolded proteins and lead several drug discovery screening endeavors aimed at modulating toxic protein concentrations.

Next to leading multiple collaborations with pharma partners, he also helmed collaborative projects with esteemed foundations such as CHDI, HDSA, and MJFF as well as with key opinion leaders in both preclinical and clinical domains, resulting in more than 50 peer-reviewed articles.
Dr. Weiss studied biochemistry at the University of Bielefeld, Germany, the University of Notre Dame, USA and the Max Planck Institute for Experimental Endocrinology, Germany. He received his Ph.D. in Neurobiology from Basel University.

Biography

Dr. Gerhard Niederfellner joined Evotec end of 2020 taking on responsibility for the internal research programs on biologics for cancer therapy. Under his leadership Evotec has developed two unique proprietary antibody platforms: one for T cell co-stimulation and one for best-in-class NK cell engagement.

After having started his career in the pharma industry with small molecule drug development at Eli Lilly in Hamburg, Gerhard joined in 2007 Roche’s Innovation Center Munich working for 10 years in roles of increasing responsibility on antibody development for oncology. From 2016 on he led as Senior Research Fellow the proprietary Nanobody portfolio development of the Belgian biotech company Ablynx. Following the take-over of Ablynx by Sanofi, Gerhard founded his own in-silico biotech and worked as freelance consultant before joining Evotec.

Biography

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet.

Contact Information

hannah.seitz@evotec.com

Contact Information

priyanka.sahasrabudhe@evotec.com

Contact Information

tanja.krainz@evotec.com